Researchers from the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine), have published a review on BH3 mimetics—a new class of drugs that are reshaping the treatment landscape for acute myeloid leukemia (AML), one of the most aggressive and treatment-resistant blood cancers. The work is published in Nature Reviews Clinical Oncology.
This article was originally published on MedicalXpress.com
Fostering a rewarding and fulfilling relationship is no easy task. You and your partner are only human, and, as the saying goes, you are going to make mistakes. However, learning the common relationship mistakes and […]
As a health and wellness enthusiast, I have always been interested in the role of supplements in promoting optimal health. In Canada, there are many supplements available on the market, each with different benefits and […]
For at least three decades, researchers have gathered evidence that chronic stress puts pressure on the body to constantly adjust itself to restore physiological stability. This process is known as allostatic load and it creates a cascade […]
© 2025 SimplyWell.ca